Abstract
Background Deciding on intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients with reported recent direct oral anticoagulant (DOAC) intake remains challenging due to concerns about hemorrhagic risk and limited real-world evidence. This study characterizes AIS patients with recent DOAC use treated at a comprehensive stroke center, routinely performing quantitative anticoagulation testing.
Methods In this retrospective, registry-based study, we analyzed clinical and procedural data from AIS patients with recent DOAC intake and calibrated anti-factor IIa/Xa activity measured within three hours of admission. Patients were treated at the University Hospital Essen between March 2017 and October 2023.
Results Among 469 included patients, anti-factor IIa/Xa activity was ≤30 ng/ml in 28%, >30–≤50 ng/ml in 9%, >50–≤75 ng/ml in 9%, >75–≤100 ng/ml in 9% and >100 ng/ml in 45%. Lower DOAC levels correlated with severe stroke symptoms at admission (ρ = −0.263, p <0.001). IVT was administered to 33.5% of patients with DOAC levels ≤50 ng/ml, compared to only 4% among those with levels >50 ng/ml, the majority of whom received prior reversal with idarucizumab. Symptomatic intracranial haemorrhage (sICH) occurred in 4% of IVT-treated and 1% of non-IVT-treated patients, without association to anticoagulation status.
Conclusion A considerable proportion of AIS patients with recent DOAC intake exhibited minimal or no anticoagulant activity at presentation. Those with the lowest levels also showed highest stroke severity. IVT was safe across all DOAC level groups, with low and comparable sICH rates. These findings support the rationale for a randomized trial evaluating IVT without prior DOAC level testing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors declare that the presented work was conducted without any external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by the Ethics committee of the medical faculty of the University Duisburg-Essen (18-8408-BO).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The authors declare that all supporting data are available within the manuscript.
